Female Preponderance in Congenital Adrenal Hyperplasia due to CYP21 Deficiency in England: Implications for Neonatal Screening
- 1 January 2005
- journal article
- research article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 63 (1), 22-28
- https://doi.org/10.1159/000082896
Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase (CYP21) deficiency causes symptoms ranging from life-threatening neonatal adrenal crises to minimal virilization in adulthood. The relationship between CYP21 genotype and phenotypic markers in a non-screened population of 73 CAH children (44 female, 29 male; 54 white, 19 Asian) treated at the Royal Manchester Children’s Hospital was investigated and ethnic and sex differences assessed. The patients were categorized according to the mutation on the mildest allele. The age at the time of diagnosis differed significantly between the groups (p = 0.02): all 25 Null and 25 of 26 of the I2 splice patients were diagnosed during the neonatal period, whereas 7 of 11 I172N patients were diagnosed late. Degree of female genital virilization, 17-hydroxyprogesterone level at diagnosis, and fludrocortisone requirement during the 1st year of treatment correlated with the genotype, although Asian Null patients required more fludrocortisone than their white counterparts (p = 0.055). There was an equal sex ratio in both the I2 splice (12 female/14 male) and I172N (5 female/6 male) groups. However, in the Null group, the ratio was 4.0 (20 female/5 male; p = 0.003), suggesting that some Null male infants perish before being clinically detected to have CYP21 deficiency. Our findings strongly support the need for implementation of a neonatal screening programme for CAH in the UK which may reduce the male infant mortality.Keywords
This publication has 11 references indexed in Scilit:
- Screening for neonatal endocrinopathies: rationale, methods and resultsSeminars in Neonatology, 2004
- Evaluation of Neonatal Screening for Congenital Adrenal HyperplasiaHormone Research in Paediatrics, 2001
- Procedure for Neonatal Screening for Congenital Adrenal Hyperplasia due to 21-Hydroxylase DeficiencyHormone Research in Paediatrics, 2001
- Congenital Adrenal Hyperplasia due to 21-Hydroxylase DeficiencyEndocrine Reviews, 2000
- Genotyping Is a Valuable Diagnostic Complement to Neonatal Screening for Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 1999
- Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal HyperplasiaPEDIATRICS, 1998
- Benefits of Neonatal Screening for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in SwedenPEDIATRICS, 1998
- Population-Wide Evaluation of Disease Manifestation in Relation to Molecular Genotype in Steroid 21-Hydroxylase (CYP21) Deficiency: Good Correlation in a Well Defined PopulationJournal of Clinical Endocrinology & Metabolism, 1997
- Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17α-hydroxyprogesterone to gestational ageScreening, 1994
- Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestationJournal of Clinical Endocrinology & Metabolism, 1994